World Alzheimer’s Month: Where could the next Alzheimer’s treatment come from?
Alzheimer’s research is gaining ground. Recently, two new drugs—lecanemab and donanemab—have proven to significantly slow the spread of the disease in clinical trials
Alzheimer’s research is gaining ground. Recently, two new drugs—lecanemab and donanemab—have proven to significantly slow the spread of the disease in clinical trials
Dr. Tom Massey joins the UK DRI at Cardiff where, as a clinician scientist, he wants to bridge the gap between the lab and the clinic, developing new therapeutic targets for Huntington’s disease (HD) and related conditions.
Ahead of the next general election campaign, Alzheimer’s Research UK has set out a series of calls for party leaders to tackle the increasing pressure that dementia places on society, the NHS, and the economy.
A simple, BRACE funded test for early diagnosis of Alzheimer’s disease could soon be helping patients and their families at the Bristol Brain Centre.
A new app to help create more dementia-friendly environments is now live after being developed and tested in the north of Wales.
A US federal initiative to improve access to care for individuals living with dementia
UK perspective on NHS readiness to embrace new dementia medications
Mediterranean diet has been demonstrated to help with brain health and is easy to incorporate into existing eating habits
FDA approval of Leqembi which is one of the new dementia disease modifying drugs